Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Geptanolimab · APL-501, GB-226

Monoclonal antibody · Inhibitor of programmed cell death 1 (PD-1) (PDCD1) · developed by Genor Biopharma Co.

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is Geptanolimab?

Geptanolimab is a humanized IgG4 monoclonal antibody that binds the PD-1 receptor on T cells, blocking its interaction with PD-L1 and PD-L2 and thereby restoring T-cell activation. It is being studied in hepatocellular carcinoma and renal cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
APL-501, GB-226, CBT-501, genolimzumab
Drug type
Monoclonal antibody
Targets
programmed cell death 1 (PD-1) (PDCD1)
Mechanism
Inhibitor of programmed cell death 1 (PD-1) (PDCD1)
Pathways
T-cell activation, PD-1/PD-L1 signaling
Therapy area
Oncology
Developer
Genor Biopharma Co., Ltd.
In trials of
APLM
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
FME52R2SGN

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03655613 Phase 1/2 Hepatocellular Carcinoma Terminated APLM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatocellular CarcinomaRenal Cell Carcinoma

Other drugs acting on PDCD1

Berahyaluronidase Alfa and Pembrolizumab FDA approved Nivolumab FDA approved Pembrolizumab FDA approved Toripalimab FDA approved Atigotatug/Nivolumab Phase 1 Balstilimab Phase 2/3 BPT567 Phase 1 Budigalimab Phase 2/3 Cadonilimab Early Phase 1 CDX-585 Phase 1 CTX-8371 Phase 1 Ivonescimab Phase 3

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.